Uncertainty remains regarding the presence and magnitude of any improvement in anticancer efficacy of the strategy of combined inhibition of the VEGFR and EGFR signaling pathways for advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.